Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'xanomeline' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 34 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Christopoulos, A
      From 'captive' agonism to insurmountable antagonism: Demonstrating the power of analytical pharmacology

      CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
    2. Christopoulos, A; Grant, MKO; Ayoubzadeh, N; Kim, ON; Sauerberg, P; Jeppesen, L; El-Fakahany, EE
      Synthesis and pharmacological evaluation of dimeric muscarinic acetylcholine receptor agonists

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    3. Carey, GJ; Billard, W; Binch, H; Cohen-Williams, M; Crosby, G; Grzelak, M; Guzik, H; Kozlowski, JA; Lowe, DB; Pond, AJ; Tedesco, RP; Watkins, RW; Coffin, VL
      SCH 57790, a selective muscarinic M-2 receptor antagonist, releases acetylcholine and produces cognitive enhancement in laboratory animals

      EUROPEAN JOURNAL OF PHARMACOLOGY
    4. Aubrey, KR; Vandenberg, RJ
      N[3-(4 '-fluorophenyl)-3-(4 '-phenylphenoxy)propyl]sarcosine (NFPS) is a selective persistent inhibitor of glycine transport

      BRITISH JOURNAL OF PHARMACOLOGY
    5. Bymaster, FP; Carter, PA; DeLapp, NW; Calligaro, DO; Felder, CC
      Receptor reserve of phosphoinositide-coupled muscarinic receptors in mousehippocampus in vivo

      BRAIN RESEARCH
    6. Perry, KW; Nisenbaum, LK; George, CA; Shannon, HE; Felder, CC; Bymaster, FP
      The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex

      BIOLOGICAL PSYCHIATRY
    7. Korczyn, AD
      Muscarinic M1 agonists in the treatment of Alzheimer's disease

      EXPERT OPINION ON INVESTIGATIONAL DRUGS
    8. Shannon, HE; Rasmussen, K; Bymaster, FP; Hart, JC; Peters, SC; Swedberg, MDB; Jeppesen, L; Sheardown, MJ; Sauerberg, P; Fink-Jensen, A
      Xanomeline, an M-1/M-4 preferring muscarinic cholinergic receptor agonist,produces antipsychotic-like activity in rats and mice

      SCHIZOPHRENIA RESEARCH
    9. Forlenza, OV; Spink, JM; Dayanandan, R; Anderton, BH; Olesen, OF; Lovestone, S
      Muscarinic agonists reduce tau phosphorylation in non-neuronal cells via GSK-3 beta inhibition and in neurons

      JOURNAL OF NEURAL TRANSMISSION
    10. Leusch, A; Troger, W; Greischel, A; Roth, W
      Pharmacokinetics of the M1-agonist talsaclidine in mouse, rat, rabbit and monkey, and extrapolation to man

      XENOBIOTICA
    11. Iwata, N; Kozuka, M; Hara, T; Kaneko, T; Tonohiro, T; Sugimoto, M; Nittsu, Y; Kondo, Y; Yamamoto, T; Sakai, J; Nagano, M
      Activation of cerebral function by CS-932, a functionally selective M-1 partial agonist: Neurochemical characterization and pharmacological studies

      JAPANESE JOURNAL OF PHARMACOLOGY
    12. Bymaster, FP; Shannon, HE; Rasmussen, K; DeLapp, NW; Ward, JS; Calligaro, DO; Mitch, CH; Whitesitt, C; Ludvigsen, TS; Sheardown, M; Swedberg, M; Rasmussen, T; Olesen, PH; Jeppesen, L; Sauerberg, P; Fink-Jensen, A
      Potential role of muscarinic receptors in schizophrenia

      LIFE SCIENCES
    13. Shannon, HE; Hart, JC; Bymaster, FP; Calligaro, DO; Delapp, NW; Mitch, CH; Ward, JS; Fink-Jensen, A; Sauerberg, P; Jeppesen, L; Sheardown, MJ; Swedberg, MDB
      Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    14. Francis, PT; Palmer, AM; Snape, M; Wilcock, GK
      The cholinergic hypothesis of Alzheimer's disease: a review of progress - Reply

      JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
    15. Jeppesen, L; Olesen, PH; Hansen, L; Sheardown, MJ; Thomsen, C; Rasmussen, T; Jensen, AF; Christensen, MS; Rimvall, K; Ward, JS; Whitesitt, C; Calligaro, DO; Bymaster, FP; Delapp, NW; Felder, CC; Shannon, HE; Sauerberg, P
      1-(1,2,5-thiadiazol-4-yl)-4-azatricyclo[2.2.1.0(2,6)]heptanes as new potent muscarinic M-1 agonists: Structure-activity relationship for 3-aryl-2-propyn-1-yloxy and 3-aryl-2-propyn-1-ylthio derivatives

      JOURNAL OF MEDICINAL CHEMISTRY
    16. Wood, MD; Murkitt, KL; Ho, M; Watson, JM; Brown, F; Hunter, AJ; Middlemiss, DN
      Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM(1), hM(2), hM(3), hM(4) and hM(5) using microphysiometry

      BRITISH JOURNAL OF PHARMACOLOGY
    17. Cutler, NR; Sramek, JJ
      Optimizing drug development for the next generation of Alzheimer's diseasecompounds

      ALZHEIMERS REPORTS
    18. SIMONSON W
      PROMISING AGENTS FOR TREATING ALZHEIMERS-DISEASE

      American journal of health-system pharmacy
    19. PLATE R; PLAUM MJM; PINTAR P; JANS CG; DEBOER T; DIJCKS FA; RUIGT G; ANDREWS JS
      SYNTHESIS, AND IN-VITRO AND IN-VIVO MUSCARINIC PHARMACOLOGICAL PROPERTIES OF A SERIES OF 1,6-DIHYDRO-5-(4H)-PYRIMIDINONE OXIMES

      Bioorganic & medicinal chemistry
    20. Watson, J; Brough, S; Coldwell, MC; Gager, T; Ho, M; Hunter, AJ; Jerman, J; Middlemiss, DN; Riley, GJ; Brown, AM
      Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors

      BRITISH JOURNAL OF PHARMACOLOGY
    21. BYMASTER FP; CARTER PA; PETERS SC; ZHANG W; WARD JS; MITCH CH; CALLIGARO DO; WHITESITT CA; DELAPP N; SHANNON HE; RIMVALL K; JEPPESEN L; SHEARDOWN MJ; FINKJENSEN A; SAUERBERG P
      XANOMELINE COMPARED TO OTHER MUSCARINIC AGENTS ON STIMULATION OF PHOSPHOINOSITIDE HYDROLYSIS IN-VIVO AND OTHER CHOLINOMIMETIC EFFECTS

      Brain research
    22. BODICK NC; OFFEN WW; SHANNON HE; SATTERWHITE J; LUCAS R; VANLIER R; PAUL SM
      THE SELECTIVE MUSCARINIC AGONIST XANOMELINE IMPROVES BOTH THE COGNITIVE DEFICITS AND BEHAVIORAL SYMPTOMS OF ALZHEIMER-DISEASE

      Alzheimer disease and associated disorders
    23. BYMASTER FP; WHITESITT CA; SHANNON HE; DELAPP N; WARD JS; CALLIGARO DO; SHIPLEY LA; BUELKESAM JL; BODICK NC; FARDE L; SHEARDOWN MJ; OLESEN PH; HANSEN KT; SUZDAK PD; SWEDBERG MDB; SAUERBERG P; MITCH CH
      XANOMELINE - A SELECTIVE MUSCARINIC AGONIST FOR THE TREATMENT OF ALZHEIMERS-DISEASE

      Drug development research
    24. SABB AL; STEIN RP; VOGEL RL; TASSE R; AMBURN S; FAIRMAN DK; KOWAL D; MALHOTRA D; BOAST CA; BARTOLOMEO A; MORRIS H; SAILER T; MOYER JA; ABOUGHARBIA M; HO DM
      WAY-131256 IS AN ORALLY-ACTIVE, EFFICACIOUS, AND IN-VIVO FUNCTIONALLYSELECTIVE M-1 AGONIST

      Drug development research
    25. MEIER E; FREDERIKSEN K; NIELSEN M; LEMBOL HL; PEDERSEN H; HYTTEL J
      PHARMACOLOGICAL IN-VITRO CHARACTERIZATION OF THE ARECOLINE BIOISOSTERE, LU 25-109-T, A MUSCARINIC COMPOUND WITH M-1-AGONISTIC AND M-2 M-3-ANTAGONISTIC PROPERTIES/

      Drug development research
    26. MEDINA A; BODICK N; GOLDBERGER AL; MACMAHON M; LIPSITZ LA
      EFFECTS OF CENTRAL MUSCARINIC-1 RECEPTOR STIMULATION ON BLOOD-PRESSURE REGULATION

      Hypertension
    27. IHL R; KRETSCHMAR C
      EVALUATION OF NOOTROPICA IN THE PRACTICE

      Nervenarzt
    28. JAKUBIK J; BACAKOVA L; ELFAKAHANY EE; TUCEK S
      POSITIVE COOPERATIVITY OF ACETYLCHOLINE AND OTHER AGONISTS WITH ALLOSTERIC LIGANDS ON MUSCARINIC ACETYLCHOLINE-RECEPTORS

      Molecular pharmacology
    29. CHRISTOPOULOS A; ELFAKAHANY EE
      NOVEL PERSISTENT ACTIVATION OF MUSCARINIC M-1 RECEPTORS BY XANOMELINE

      European journal of pharmacology
    30. HARTVIG P; TORSTENSON R; BJURLING P; FASTH KJ; LANGSTROM B; NORDBERG A
      REGIONAL BRAIN DISTRIBUTION AND BINDING OF THE MUSCARINIC RECEPTOR AGONIST CI-979 STUDIED BY POSITRON EMISSION TOMOGRAPHY IN THE MONKEY

      Dementia and geriatric cognitive disorders
    31. FARDE L; SUHARA T; HALLDIN C; NYBACK H; NAKASHIMA Y; SWAHN CG; KARLSSON P; GINOVART N; BYMASTER FP; SHANNON HE; FOGED C; SUZDAK PD; SAUERBERG P
      PET STUDY OF THE M(1)-AGONISTS [C-11] XANOMELINE AND [C-11] BUTYLTHIO-TZTP IN MONKEY AND MAN

      Dementia
    32. SRAMEK JJ; CUTLER NR; HURLEY DJ; SEIFERT RD
      THE UTILITY OF SALIVARY AMYLASE AS AN EVALUATION OF M(3) MUSCARINIC AGONIST ACTIVITY IN ALZHEIMERS-DISEASE

      Progress in neuro-psychopharmacology & biological psychiatry
    33. ECKOLS K; BYMASTER FP; MITCH CH; SHANNON HE; WARD JS; DELAPP NW
      THE MUSCARINIC M1 AGONIST XANOMELINE INCREASES SOLUBLE AMYLOID PRECURSOR PROTEIN RELEASE FROM CHINESE-HAMSTER OVARY-M1 CELLS

      Life sciences
    34. PERIYASAMY S; MESSER WS; ROKNICH S; SAUERBERG P; HOSS W
      1,2,5-THIADIAZOLE DERIVATIVES OF ARECOLINE STIMULATE M(1) RECEPTORS COUPLED TO PHOSPHOINOSITIDE TURNOVER

      Brain research


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/02/20 alle ore 23:20:11